HCM
HUTCHMED (China) Ltd
Next earnings Aug 5, 2026
$11.44
▲ +6.82%$11.44▼ -24.24%
over 1Y
L $9.99H $19.21
Today+6.8%
1W+11.2%
1M-0.7%
3M-25.8%
YTD-16.2%
1Y-24.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 26 analysts
Buy
Strong net margin (83.3%); but revenue fell -13.0% YoY.
Revenue (FY2025) $549M · FY2025
The read
Middling fundamentals offset by an attractive price (~73% below fair value) — worth a look on the value angle.
HUTCHMED (China) Ltd shows $549M in FY2025 revenue (-13.0% YoY), a 83.3% net margin, and 36.9% ROE.
Supporting the case: strong net margin (83.3%); high return on equity (36.9%); conservative balance sheet (liabilities/equity 0.41x).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $356M | $426M | $838M | $630M | $549M |
| Gross profit | — | — | — | — | — |
| Operating income | -$328M | -$408M | $18.4M | -$43.7M | -$39.2M |
| Net income | -$195M | -$361M | $101M | $37.7M | $457M |
| Diluted EPS | -$0.25 | -$0.43 | $0.12 | $0.04 | $0.52 |
| Net margin | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.99B
EV / EBITDA—
EV / Sales3.6
EV / FCF—
P / FCF—
PEG (trailing)0.02
Earnings yield23.2%
FCF yield-4.0%
Quality & risk
ROIC (est.)-2.3%
Free cash flow-$78.8M
Total debt$93.2M
Net cash-$21.8M
Altman Z-Score3.15 safe
Piotroski F-Score4/8
Capital returns
Buyback yield1.8%
Dividend yield (est.)—
Shareholder yield1.8%
Shares Δ YoY+0.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗6-KPeriod ending 2026-07-022026-07-02open ↗6-KPeriod ending 2026-06-302026-06-30open ↗6-KPeriod ending 2026-06-292026-06-29open ↗6-KPeriod ending 2026-06-252026-06-25open ↗6-KPeriod ending 2026-06-122026-06-12open ↗S-8Filing2026-06-09open ↗6-KPeriod ending 2026-06-052026-06-05open ↗6-KPeriod ending 2026-05-222026-05-22open ↗6-KPeriod ending 2026-05-212026-05-21open ↗4Period ending 2026-05-202026-05-21open ↗4Period ending 2026-05-202026-05-21open ↗4Period ending 2026-05-202026-05-21open ↗
Frequently asked
- Is HUTCHMED (China) Ltd (HCM) a buy?
- HCM currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong net margin (83.3%); but revenue fell -13.0% YoY.
- What is HCM's fair value?
- A Modified-Graham model based on HCM's SEC fundamentals estimates a fair value of about $19.76. It is an estimate from reported earnings, not a price target.
- Is HCM overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, HCM currently appears undervalued relative to its SEC-grounded earnings power.
- What is HUTCHMED (China) Ltd's quality score?
- HCM scores 64.64037714869028/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001648257, latest 6-K filed 2026-07-02) · EODHD · as of 7/4/2026, 12:52:43 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.